Clinical Trial Update: Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a combined DTaP-IPV-HepB-PRP-T vaccine given after a primary series of DTaP-IPV-HepB-PRP-T or Infanrix Hexa; results were posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTaP-IPV-HepB-PRP-T combined vaccine (diphtheria, tetanus, acellular pertussis, inactivated poliovirus vaccine, hepatitis B vaccine, Haemophilus influenzae type b conjugate vaccine)
• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2013-06-26